Relationship of frontal D2/3 binding potentials to cognition: A study of antipsychotic-naive schizophrenia patients

International Journal of Neuropsychopharmacology

Volumn 16, Issue 1, 2013, Pages 23-36

  Fagerlund, Birgitte ^a   Pinborg, Lars H ^a   Mortensen, Erik Lykke ^a   Friberg, Lars ^a   Baaré, William F C ^a,b   Gade, Anders ^a   Svarer, Claus ^a   Glenthøj, Birte Y ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Center for Integrated Molecular Brain Imaging   (Denmark)

Author keywords

Antipsychotic naive; cognition; dopamine; schizophrenia; SPECT

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; EPIDEPRIDE; EPIDEPRIDE I 123; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; FRONTAL CORTEX; HUMAN; ICD-10; IN VIVO STUDY; MALE; MENTAL DEFICIENCY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCHIZOPHRENIA; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERBAL COMMUNICATION;

ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; CASE-CONTROL STUDIES; COGNITION; CROSS-SECTIONAL STUDIES; FEMALE; FRONTAL LOBE; HUMANS; MALE; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84871530431     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114571200003X     Document Type: Article

References (65)

1. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, et al. (2002). Prefrontal dopamine D1 receptors and working memory in schizophrenia. Journal of Neuroscience 22, 3708-3719.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington, DC: American Psychiatric Association.
3. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994). Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berlin) 116, 143-151.
4. Backman L, Ginovart N, Dixon RA, Wahlin TB, et al. (2000). Age-related cognitive deficits mediated by changes in the striatal dopamine system. American Journal of Psychiatry 157, 635-637.
5. Barch DM, Carter CS, Arnsten A, Buchanan RW, et al. (2009). Selecting paradigms from cognitive neuroscience for translation into use in clinical trials : proceedings of the third CNTRICS meeting. Schizophrenia Bulletin 35, 109-114.
6. Bilder RM, Goldman RS, Robinson D, Reiter G, et al. (2000). Neuropsychology of first-episode schizophrenia : initial characterization and clinical correlates. American Journal of Psychiatry 157, 549-559.
7. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, et al. (2006). D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research 85, 232-244.
8. Carlsson A (2006). The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 (Suppl. 1), S10-S14.
9. Chudasama Y, Robbins TW (2004). Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task : implications for schizophrenia. Psychopharmacology (Berlin) 174, 86-98.
10. Chudasama Y, Robbins TW (2006). Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biological Psychology 73, 19-38.
11. Cropley VL, Fujita M, Innis RB, Nathan PJ (2006). Molecular imaging of the dopaminergic system and its association with human cognitive function. Biological Psychiatry 59, 898-907.
12. Durstewitz D, Seamans JK (2008). The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biological Psychiatry 64, 739-749.
13. Fagerlund B, Mackeprang T, Gade A, Hemmingsen RP, et al. (2004). Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naÍve schizophrenic patients. CNS Spectrums 9, 364-374.
14. Floresco SB, Magyar O (2006). Mesocortical dopamine modulation of executive functions : beyond working memory. Psychopharmacology (Berlin) 188, 567-585.
15. Floresco SB, Magyar O, Ghods-Sharifi S, Vexelman C, et al. (2006). Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 31, 297-309.
16. Glenthoj B, Mogensen J, Laursen H, Holm S, et al. (1993). Electrical sensitization of the meso-limbic dopaminergic system in rats : a pathogenetic model for schizophrenia. Brain Research 619, 39-54.
17. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, et al. (2006). Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biological Psychiatry 60, 621-629.
18. Glickstein SB, Desteno DA, Hof PR, Schmauss C (2005). Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cerebral Cortex 15, 1016-1024.
19. Granon S, Passetti F, Thomas KL, Dalley JW, et al. (2000). Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. Journal of Neuroscience 20, 1208-1215.
20. Grunder G, Fellows C, Janouschek H, Veselinovic T, et al. (2008). Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia : an [18F]fallypride PET study. American Journal of Psychiatry 165, 988-995.
21. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, et al. (2001). Stability and course of neuropsychological deficits in schizophrenia. Archives of General Psychiatry 58, 24-32.
22. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia : version III-the final common pathway. Schizophrenia Bulletin 35, 549-562.
23. Innis RB, Cunningham VJ, Delforge J, Fujita M, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow Metabolism 27, 1533-1539.
24. Kay SR (1991). Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel.
25. Kessler RM, Ansari MS, de Paulis T, Schmidt DE, et al. (1991a). High affinity dopamine D2 receptor radioligands. 1. Regional rat brain distribution of iodinated benzamides. Journal of Nuclear Medicine 32, 1593-1600.
26. Kessler RM, Ansari MS, Schmidt DE, de Paulis T, et al. (1991b). High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Science 49, 617-628.
27. Kessler RM, Votaw JR, Schmidt DE, Ansari MS, et al. (1993). High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride : in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Science 53, 241-250.
28. Kessler RM, Woodward ND, Riccardi P, Li R, et al. (2009). Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biological Psychiatry 65, 1024-1031.
29. Kimberg DY, d'Esposito M, Farah MJ (1997). Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 8, 3581-3585.
30. Kuikka JT, Akerman KK, Hiltunen J, Bergstrom KA, et al. (1997). Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. European Journal of Nuclear Medicine 24, 483-487.
31. Laruelle M (2000). The role of endogenous sensitization in the pathophysiology of schizophrenia : implications from recent brain imaging studies. Brain Research Brain Research Review 31, 371-384.
32. Lumme V, Aalto S, Ilonen T, Nagren K, et al. (2007). Dopamine D2/D3 receptor binding in the anterior cingulate cortex and executive functioning. Psychiatry Research : Neuroimaging 156, 69-74.
33. Laws KR (1999). A meta-analytic review of Wisconsin card sorting studies in schizophrenia: general intellectual deficit in disguise? Cognitive Neuropsychiatry 4, 1-35.
34. MacDonald SW, Cervenka S, Farde L, Nyberg L, et al. (2009). Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning. Neuropsychologia 47, 2299-2304.
35. Mehta MA, Hinton EC, Montgomery AJ, Bantick RA, et al. (2005). Sulpiride and mnemonic function: effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers. Journal of Psychopharmacology 19, 29-38.
36. Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, et al. (2004). Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology (Berlin) 176, 331-342.
37. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999). Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology (Berlin) 146, 162-174.
38. Mehta MA, Swainson R, Ogilvie AD, Sahakian J, et al. (2001). Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Psychopharmacology (Berlin) 159, 10-20.
39. Mizrahi R, Rusjan P, Agid O, Graff A, et al. (2007). Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors : a PET study in schizophrenia. American Journal of Psychiatry 164, 630-637.
40. Muller U, von Cramon DY, Pollmann S (1998). D1-vs. D2-receptor modulation of visuospatial working memory in humans. Journal of Neuroscience 18, 2720-2728.
41. Nieuwenstein MR, Aleman A, de Haan EH (2001). Relationship between symptom dimensions and neurocognitive functioning in schizophrenia : a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. Journal of Psychiatry Research 35, 119-125.
42. Palmer BW, Dawes SE, Heaton RK (2009). What do we know about neuropsychological aspects of schizophrenia? Neuropsychology Review 19, 365-384.
43. Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, et al. (2000). Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse 36, 322-329.
44. Pinborg LH, Videbaek C, Ziebell M, Mackeprang T, et al. (2007). [123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable : implications for the use of cerebellum as a reference region. Neuroimage 34, 1450-1453.
45. Reeves SJ, Grasby PM, Howard RJ, Bantick RA, et al. (2005). A positron emission tomography (PET) investigation of the role of striatal dopamine (D2) receptor availability in spatial cognition. Neuroimage 28, 216-226.
46. Sawaguchi T, Goldman-Rakic PS (1991). D1 dopamine receptors in prefrontal cortex : involvement in working memory. Science 251, 947-950.
47. Sawaguchi T, Goldman-Rakic PS (1994). The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of Rhesus monkeys performing an oculomotor delayed-response task. Journal of Neurophysiology 71, 515-528.
48. Schroder J, Bubeck B, Silvestri S, Demisch S, et al. (1997). Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia : an [123I]iodobenzamide single photon emission computed tomography study. Psychiatry Research 75, 115-123.
49. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
50. Seeman P, Lee T (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219.
51. Suhara T, Okubo Y, Yasuno F, Sudo Y, et al. (2002). Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Archives of General Psychiatry 59, 25-30.
52. Takahashi H, Kato M, Takano H, Arakawa R, et al. (2008). Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. Journal of Neuroscience 28, 12032-12038.
53. Talvik M, Nordstrom AL, Okubo Y, Olsson H, et al. (2006). Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Research 148, 165-173.
54. Talvik M, Nordstrom AL, Olsson H, Halldin C, et al. (2003). Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia : a PET study with [11C]FLB 457. International Journal of Neuropsychopharmacology 6, 361-370.
55. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, et al. (2003). Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Molecular Psychiatry 8, 453-455.
56. Tuppurainen H, Kuikka JT, Laakso MP, Viinamaki H, et al. (2006). Midbrain dopamine D2/3 receptor binding in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 256, 382-387.
57. Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, et al. (2009). Dopamine D(2/3) receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry and Clinical Neuroscience 63, 529-537.
58. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, et al. (2007). Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nature Neuroscience 10, 376-384.
59. Volkow ND, Gur RC, Wang GJ, Fowler JS, et al. (1998). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. American Journal of Psychiatry 155, 344-349.
60. Williams GV, Goldman-Rakic PS (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572-575.
61. WHO (1994). Schedules for Clinical Assessment in Neuropsychiatry. Geneva: World Health Organization.
62. Yang YK, Yeh TL, Chiu NT, Lee IH, et al. (2004). Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia. Psychiatry Research 131, 209-216.
63. Yasuno F, Suhara T, Okubo Y, Ichimiya T, et al. (2005). Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia. Psychiatry Research 138, 197-207.
64. Yasuno F, Suhara T, Okubo Y, Sudo Y, et al. (2004). Low dopamine D(2) receptor binding in subregions of the thalamus in schizophrenia. American Journal of Psychiatry 161, 1016-1022.
65. Yoder KK, Hutchins GD, Morris ED, Brashear A, et al. (2004). Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophrenia Research 71, 371-375.